Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OptiBiotix Health ( (GB:OPTI) ) just unveiled an update.
OptiBiotix Health has launched a double-blind, placebo-controlled clinical trial with Hull University Teaching Hospital NHS Trust to assess whether its patented prebiotic fibre complex WellBiome can improve cardiac surgery outcomes and reduce costs for the NHS. The six-week pre-operative supplementation study of up to 60 patients will measure time in intensive care, overall hospital stay and post-operative complications, alongside a formal cost-savings analysis.
WellBiome, developed with UK universities, is designed to enhance gut microbiome diversity and carries European and US health claims spanning gut, bone, cardiovascular, muscle, brain and psychological health, aligning with rising global consumer focus on gut health. If the trial demonstrates clinical and economic benefits, WellBiome could be positioned as a standard preoperative care option for NHS surgical patients, strengthening OptiBiotix’s role in evidence-based microbiome interventions and potentially opening broader healthcare adoption.
The most recent analyst rating on (GB:OPTI) stock is a Hold with a £7.50 price target. To see the full list of analyst forecasts on OptiBiotix Health stock, see the GB:OPTI Stock Forecast page.
Spark’s Take on GB:OPTI Stock
According to Spark, TipRanks’ AI Analyst, GB:OPTI is a Neutral.
The score is weighed down primarily by persistent losses and cash burn despite strong 2024 revenue growth, and by weak technicals showing a sustained downtrend with negative momentum. A debt-free balance sheet provides some support, but valuation remains difficult to justify with negative earnings and no dividend yield provided.
To see Spark’s full report on GB:OPTI stock, click here.
More about OptiBiotix Health
OptiBiotix Health plc is a UK-based life sciences company focused on developing microbiome-modulating technologies and products to help prevent and manage human disease. Its portfolio includes prebiotic ingredients such as SlimBiome, WellBiome, SweetBiotix and Microbiome Modulators, alongside interests in skincare and probiotics, targeting the fast-growing global market for gut and metabolic health solutions.
Average Trading Volume: 462,976
Technical Sentiment Signal: Sell
Current Market Cap: £6.56M
See more data about OPTI stock on TipRanks’ Stock Analysis page.